Indication
As monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).

Medicine details

Medicine name:
alectinib hydrochloride (Alecensa)
SMC ID:
SMC2012
Pharmaceutical company
Roche
BNF chapter
Malignant disease and immunosuppression
Submission type
Resubmission
Status
Advice due date:
13 August 2018
SMC meeting date:
03 July 2018
Patient group submission deadline:
04 June 2018